checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


Psoriasis impacts patients' skin and beyond1,2

Psoriasis is a systemic disease characterized by multiple manifestations, including some that are difficult to treat1,2

Addressing individual treatment goals beyond skin clearance is crucial to patient satisfaction3,4

 

Click on a domain to see the efficacy of OTEZLA in psoriasis

References: 1. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011:303:1–10. 2. Kavanaugh A, Gladman DD, Edwards CJ, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Longterm (104-Week) Improvement in Fatigue in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase 3, Randomized, Controlled Trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7–11, 2015; San Francisco, CA. 3. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881. 4. WHO Psoriasis Report 2016.


Select an e-mail client to share

close x